Trials / Completed
CompletedNCT01547715
Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Subjects From 2 to 75 Years of Age in India
A Phase 3, Multi-center, Open-label Study to Evaluate Immunogenicity and Safety of Novartis Meningococcal ACWY Conjugate Vaccine (MenACWY-CRM) in Healthy Subjects From 2 to 75 Years of Age in India.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 180 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 2 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
This study will evaluate the immunogenicity of a single injection of Novartis Meningococcal ACWY conjugate vaccine in healthy subjects from the age of 2 years and above in India.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Meningococcal ACWY conjugate vaccine | All subjects received a single dose of Meningococcal ACWY conjugate vaccine |
Timeline
- Start date
- 2012-03-01
- Primary completion
- 2014-04-01
- Completion
- 2014-04-01
- First posted
- 2012-03-08
- Last updated
- 2018-10-09
- Results posted
- 2014-12-31
Locations
4 sites across 1 country: India
Source: ClinicalTrials.gov record NCT01547715. Inclusion in this directory is not an endorsement.